Drug Trial Radar · NCT06012136
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Aug 24, 2023
Primary completion
Jun 9, 2026
Study completion Jun 9, 2026
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to investigate safety and tolerability following single and multiple ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants. The study will also describe the pharmacokinetics following single and multiple ascending SC and IM doses of capsid inhibitors in healthy participants.
Conditions
- HIV Infections
Interventions
VH4004280Drug
VH4004280 will be administered.
PlaceboDrug
Placebo will be administered.
VH4011499Drug
VH4011499 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD: Number of Participants with Adverse Events (AEs) as per SeverityTime frame: Up to Week 52
- MAD: Number of Participants with Adverse Events (AEs) as per SeverityTime frame: Up to Week 56
- SAD: Absolute Values of Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (micromoles per liter [umol/L])Time frame: Up to Week 52
- MAD: Absolute Values of Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (micromoles per liter [umol/L])Time frame: Up to Week 56
- SAD: Change from Baseline in Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (umol/L)Time frame: Baseline (Prior to Day 1) and up to Week 52
- MAD: Change from Baseline in Liver Chemistry Parameters: Total Bilirubin and Direct Bilirubin (umol/L)Time frame: Baseline (Prior to Day 1) and up to Week 56
- SAD: Number of Participants with Maximum Toxicity Grade Change from Baseline in Liver Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT)Time frame: Up to Week 52
- MAD: Number of Participants with Maximum Toxicity Grade Change from Baseline in Liver Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT)Time frame: Up to Week 56
- SAD: Absolute Values of Liver Chemistry Parameters: Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) (International Units per liter)Time frame: Up to Week 52
- MAD: Absolute Values of Liver Chemistry Parameters: Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) (International Units per liter)Time frame: Up to Week 56
- SAD: Change from Baseline in Liver Chemistry Parameters: Alkaline Phosphatase, AST, and ALT (International Units per liter)Time frame: Baseline (Prior to Day 1) and up to Week 52
- MAD: Change from Baseline in Liver Chemistry Parameters: Alkaline Phosphatase, AST, and ALT (International Units per liter)Time frame: Baseline (Prior to Day 1) and up to Week 56
- SAD: Number of Participants with Injection Site Reactions (ISR) AE by Grade Using the DAIDS Grading ScaleTime frame: Up to Week 52
- MAD: Number of Participants with Injection Site Reactions (ISR) AE by Grade Using the DAIDS Grading ScaleTime frame: Up to Week 56
- SAD: Duration of ISR (Days) AETime frame: Up to Week 52
- MAD: Duration of ISR (Days) AETime frame: Up to Week 56
- Area Under the Plasma-concentration Time curve from Time Zero to Infinity (AUC0-inf) of VH4004280Time frame: Up to Week 52
- Area Under the Plasma-concentration Time curve from Time Zero to Infinity (AUC0-inf) of VH4011499Time frame: Up to Week 56
- Maximum Observed Plasma Concentration (Cmax) of VH4004280Time frame: Up to Week 52
- Maximum Observed Plasma Concentration (Cmax) of VH4011499Time frame: Up to Week 56
- Time of Maximum Observed Plasma Concentration (tmax) of VH4004280Time frame: Up to Week 52
- Time of Maximum Observed Plasma Concentration (tmax) of VH4011499Time frame: Up to Week 56
- Apparent Terminal Half-life (t1/2) of VH4004280Time frame: Up to Week 52
- Apparent Terminal Half-life (t1/2) of VH4011499Time frame: Up to Week 56
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.